Efficacy and Safety of Mitiglinide vs Acarbose in Patients With Type 2 Diabetes Mellitus

PHASE4CompletedINTERVENTIONAL
Enrollment

248

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Mitiglinide

three times a day, orally, for 12 weeks

DRUG

Acarbose

three times a day, orally, for 12 weeks

Trial Locations (6)

Unknown

The First People's Hospital of Changzhou, Changzhou

The Second People's Hospital of Huai'an, Huai'an

Department of Endocrinology, Zhongda Hospital, Institute of Diabetes, Southeast University, Nanjing

Xuzhou Central Hospital, Xuzhou

Yancheng City No.1 People's Hospital, Yancheng

Zhenjiang First People's Hospital, Zhenjiang

All Listed Sponsors
lead

Zhongda Hospital

OTHER

NCT02143765 - Efficacy and Safety of Mitiglinide vs Acarbose in Patients With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter